|
KMID : 0948320080080020033
|
|
Konyang Medical Journal
2008 Volume.8 No. 2 p.33 ~ p.39
|
|
|
PIK3CA and p53 Mutations in Breast Cancers
|
|
Sul Hae-Joung
|
|
|
Abstract
|
|
|
Background: The phosphatidylinositol 3-kinase (PI3K)-AKT signaling pathway and the p53 tumor suppresor gene
are considered to play an important role in tumorgenesis. Even though frequent PIK3CA (PI3K subunit p110a) and p53
somatic mutations have been reported previously in various kinds of human cancers, the genetic changes of PIK3CA
and p53 in human breast cancer have not been clearly identified. We screened 50 primary human breast tumors for mutations in PIK3CA and p53 in order to determine associations with clinicopathological features.
Materials and Methods : Representative areas from 50 breast cancers were selected for construction of tissue microarrays using a 5 mm punch. Immunohistochemical analyses for estrogen receptor (ER), progesterone receptor (PR), HER2, PTEN, and p53 were performed. SSCP-PCR analysis for mutation of exons 1, 9, and 20 of PIK3CA and exons 5 to 8
of p53 was carried out. The clinicopathological parameters of age at initial diagnosis, tumor size, histologic subtype, histologic grade, and lymph node metastasis were evaluated.
Results: The frequencies of PIK3CA and p53 mutations were 12% and 8%, respectively. The frequency of PIK3CA
mutations in ER-positive tumors (29%) was higher than the frequency in ER-negative tumors (6%) (p < 0.05). However,
the PIK3CA mutation status was not significantly associated with histologic type, tumor size, lymph node status, patient
age, histologic grade, or p53 mutation (p > 0.05).
Conclusion: Even though both PIK3CA and p53 mutations are not common in breast cancers, PIK3CA mutations are associated with a positive ER status (p = 0.047) in breast cancer.
|
|
|
KEYWORD
|
|
|
Breast cancer, PIK3CA, p53
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|